Dimensional Fund Advisors LP Acquires 360,629 Shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)

Dimensional Fund Advisors LP increased its position in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA - Free Report) by 17.4% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 2,430,221 shares of the biotechnology company's stock after buying an additional 360,629 shares during the quarter. Dimensional Fund Advisors LP owned about 0.80% of Iovance Biotherapeutics worth $17,979,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in IOVA. SG Americas Securities LLC purchased a new position in shares of Iovance Biotherapeutics in the 4th quarter worth about $515,000. Jennison Associates LLC acquired a new stake in Iovance Biotherapeutics during the 4th quarter worth approximately $493,000. Barclays PLC raised its holdings in Iovance Biotherapeutics by 118.8% in the third quarter. Barclays PLC now owns 604,584 shares of the biotechnology company's stock valued at $5,677,000 after buying an additional 328,284 shares during the period. Principal Financial Group Inc. lifted its position in Iovance Biotherapeutics by 59.0% during the third quarter. Principal Financial Group Inc. now owns 4,033,184 shares of the biotechnology company's stock valued at $37,872,000 after buying an additional 1,496,941 shares in the last quarter. Finally, Banque Pictet & Cie SA grew its stake in Iovance Biotherapeutics by 17.0% during the fourth quarter. Banque Pictet & Cie SA now owns 376,591 shares of the biotechnology company's stock worth $2,787,000 after buying an additional 54,832 shares during the period. Institutional investors and hedge funds own 77.03% of the company's stock.

Iovance Biotherapeutics Stock Down 44.8 %

IOVA traded down $1.42 during trading on Friday, reaching $1.75. The stock had a trading volume of 112,141,445 shares, compared to its average volume of 8,198,136. Iovance Biotherapeutics, Inc. has a 1-year low of $1.65 and a 1-year high of $12.51. The firm has a market capitalization of $584.38 million, a price-to-earnings ratio of -1.17 and a beta of 1.06. The stock has a 50 day moving average of $3.36 and a two-hundred day moving average of $6.10.

Iovance Biotherapeutics (NASDAQ:IOVA - Get Free Report) last released its earnings results on Thursday, May 8th. The biotechnology company reported ($0.36) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.25) by ($0.11). The firm had revenue of $49.32 million for the quarter, compared to analyst estimates of $83.40 million. Iovance Biotherapeutics had a negative return on equity of 58.43% and a negative net margin of 451.25%. Iovance Biotherapeutics's revenue was up 6795.1% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.42) earnings per share. On average, research analysts forecast that Iovance Biotherapeutics, Inc. will post -1.24 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts recently weighed in on the stock. The Goldman Sachs Group reduced their target price on shares of Iovance Biotherapeutics from $18.00 to $16.00 and set a "buy" rating on the stock in a report on Thursday, April 17th. Barclays decreased their price target on shares of Iovance Biotherapeutics from $22.00 to $5.00 and set an "overweight" rating for the company in a research report on Monday, April 14th. Baird R W cut Iovance Biotherapeutics from a "strong-buy" rating to a "hold" rating in a research note on Friday. HC Wainwright reduced their price target on shares of Iovance Biotherapeutics from $32.00 to $20.00 and set a "buy" rating on the stock in a research report on Friday. Finally, Robert W. Baird reduced their price objective on Iovance Biotherapeutics from $24.00 to $20.00 and set an "outperform" rating for the company in a research report on Friday, February 28th. One analyst has rated the stock with a sell rating, four have given a hold rating and seven have assigned a buy rating to the stock. According to MarketBeat.com, Iovance Biotherapeutics has a consensus rating of "Moderate Buy" and a consensus price target of $16.33.

About Iovance Biotherapeutics

Iovance Biotherapeutics, Inc, a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma.